Strive Health is a technology company.
Strive Health is the nation’s leader in value-based kidney care, transforming how we treat kidney disease by identifying patients earlier and prioritizing the right care.
Strive Health has raised $690.0M across 4 funding rounds.
Strive Health has raised $690.0M in total across 4 funding rounds.
Strive Health is a healthcare technology company specializing in value-based kidney care, delivering an integrated care system for patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD).[1][2][3] It builds the CareMultiplier™ platform—a machine learning tool that aggregates data, provides predictive insights, and enables individualized care plans—combined with high-touch, NP-led "Kidney Heroes™" care teams to slow disease progression, reduce hospitalizations, and lower costs.[2][3][6] Serving over 145,000 patients across 50 states, it partners with 6,500+ providers, payors (including Medicare Advantage and commercial plans), and health systems through risk-based arrangements, managing nearly $5 billion in annual medical spend while achieving NCQA accreditation and HITRUST certification.[2][4]
The company demonstrates strong growth momentum, including a recent $550 million capital raise, recognition as a TIME top healthtech company in 2025, Forbes' Best Startup Employer for four years, and Built In's 2025 Best Place to Work, with over 700 employees.[2][4][5]
Founded in 2018 in Denver, Colorado, Strive Health emerged to address shortcomings in traditional kidney care, which historically focuses on treatment after kidney failure rather than early intervention and prevention.[1][3] While specific founders are not detailed in available sources, the company was built by healthcare innovators aiming to shift the paradigm toward value-based models using technology and care teams.[1][2] Early traction came from forming partnerships with payors and providers, scaling to national reach, and developing CareMultiplier™ for predictive analytics, which supports proactive interventions.[3][6] Pivotal moments include NCQA accreditation for its programs and rapid expansion to serve patients nationwide, culminating in major recognitions and funding by 2025.[2][4]
Strive Health rides the value-based care trend in healthcare, where payors and providers shift from fee-for-service to outcomes-based models amid rising CKD prevalence (affecting millions) and ESKD costs exceeding $50 billion annually in the U.S.[2][3] Timing aligns with Medicare's push for programs like CKCC and the growth of Medicare Advantage, enabling Strive's risk-sharing partnerships.[3] Favorable market forces include AI advancements for predictive health analytics, hybrid virtual/in-person care (as a CB Insights highflier alongside One Medical), and demand for cost reduction in a fragmented system.[1][2] It influences the ecosystem by empowering nephrologists in value-based arrangements, setting standards for tech-enabled kidney care, and demonstrating scalable population health management.[3][6]
Strive Health is poised for continued dominance in value-based kidney care, leveraging its $550M raise to expand AI capabilities, deepen payor integrations, and potentially enter adjacent cardio-renal markets.[2] Trends like AI personalization, home-based dialysis growth, and regulatory support for risk models will accelerate its trajectory, with metrics already showing total cost reductions and better outcomes.[2][6] Its influence may evolve by standardizing preventative kidney tech across health systems, solidifying its role as the go-to partner for innovative payors—transforming a broken paradigm into patient-first care at scale.[2][3]
Strive Health has raised $690.0M in total across 4 funding rounds.
Strive Health's investors include AIX Ventures, Ascension Ventures, CapitalG, CVS Health, New Enterprise Associates, SJF Ventures, Surface Ventures, Akhil Paul, Akshay Sriprasad, Austin Walters, Joanne Bradford, Marc Benioff.
Strive Health has raised $690.0M across 4 funding rounds. Most recently, it raised $300.0M Series D in September 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $300.0M Series D | AIX Ventures, Ascension Ventures, CapitalG, CVS Health, New Enterprise Associates, SJF Ventures, Surface Ventures, Akhil Paul, Akshay Sriprasad, Austin Walters, Joanne Bradford, Marc Benioff, Ricardo Marino | |
| May 1, 2023 | $170.0M Series C | AIX Ventures, Ascension Ventures, BlueCross BlueShield Venture Partners, CapitalG, CVS Health, Mohamad Makhzoumi, New Enterprise Associates, Oak HC/FT, Sandbox Industries, SJF Ventures, Surface Ventures, Akhil Paul, Akshay Sriprasad, Austin Walters, Joanne Bradford, Marc Benioff, Ricardo Marino | |
| Mar 1, 2021 | $140.0M Series B | Ascension Ventures, CapitalG, CVS Health, Mohamad Makhzoumi | |
| Apr 1, 2019 | $80.0M Series A | Ascension Ventures, CapitalG, CVS Health, Mohamad Makhzoumi |